UBS has rated AstraZeneca as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content reflects the views of individual authors rather than wallstreetONLINE.